GLP-1 Drugs Show Benefits Beyond Weight Loss, Impacting Heart and Liver Health
Recent research highlights that GLP-1 drugs, commonly used for weight loss and diabetes management, offer significant health benefits beyond weight reduction. These medications, including Wegovy and Zepbound, are known to mimic a hormone involved in insulin secretion and appetite regulation. While clinical trials indicate that 10 to 15% of users do not experience substantial weight loss, studies reveal that these drugs can still improve heart and liver health. Notably, Wegovy has been approved by the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting about 6% of U.S. adults. The drug's ability to reduce inflammation and improve cardiovascular outcomes, such as lowering the risk of heart attacks and strokes, is independent of weight loss. This finding suggests a need to reassess how health insurers evaluate the success of GLP-1 treatments, potentially shifting focus from weight loss to broader health benefits. 
